Article citationsMore>>

R. F. Schwabe, H. Engelmann, S. Hess and H. Fricke, “Soluble CD40 in the Serum of Healthy Donors, Patients with Chronic Renal Failure, Haemodialysis and Chronic Ambulatory Peritoneal Dialysis (CAPD) Patients,” Clinical & Experimental Immunology, Vol. 117, No. 1, 1999, pp. 153-158. doi:10.1046/j.1365-2249.1999.00935.x

has been cited by the following article:

• TITLE: Clinical Significance of Plasma Levels of Soluble CD40 in Patients with Chronic Lymphocytic Leukemia

  AUTHORS: Barry D. Hock, Liam J. Fernyhough, Sheryl M. Gough, Judith L. McKenzie

  KEYWORDS: CD40; Chronic Lymphocytic Leukemia; Survival

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.3 No.1, March 28, 2013

  ABSTRACT: CD40 ligation provides signals central to chronic lymphocytic leukemia (CLL) cell survival and proliferation. The release of soluble CD40 (sCD40) may impact on both these signals and CD40 targeted therapies. In this study we investigated the prognostic significance of plasma sCD40 inuntreated CLL patients (n = 34). We report that 56% had levels higher than those of normal donors and that elevated levels were associated with significantly shorter treatment free (TFS) and overall survival. In bivariate analysis sCD40 remained a significant marker of TFS independent of Binet staging, CD38 positivity and lymphocyte count. RT-PCR analysis demonstrated that CLL cells expressed transcripts encoding putative sCD40. These results suggest sCD40 may play a role in CLL progression and that its function, prognostic significance and potential impact on antibody based therapies should be further investigated.